StreetInsider.com News Articles

Form 25-NSE Molecular Templates, Filed by: Nasdaq Stock Market LLC

Thu, 22 May 2025 15:17:00 -0400

si-local-file:///var/storage/secattach/20250522/24840158.html

Form 25-NSE Molecular Templates, Filed by: Nasdaq Stock Market LLC

Thu, 22 May 2025 15:17:00 -0400

si-local-file:///var/storage/secattach/20250522/24840158.html

Form 25-NSE Molecular Templates, Filed by: Nasdaq Stock Market LLC

Thu, 22 May 2025 15:17:00 -0400

si-local-file:///var/storage/secattach/20250522/24840158.html

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Wed, 14 May 2025 16:30:00 -0400

Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience
Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026
IND cleared by FDA for CLD-201 clinical trial

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Wed, 14 May 2025 16:30:00 -0400

Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience
Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026
IND cleared by FDA for CLD-201 clinical trial

Form 8-K Molecular Templates, For: Apr 20

Thu, 24 Apr 2025 17:00:00 -0400

si-local-file:///var/storage/secattach/20250424/24684637.html

Form 8-K Molecular Templates, For: Apr 20

Thu, 24 Apr 2025 17:00:00 -0400

si-local-file:///var/storage/secattach/20250424/24684637.html

Form 8-K Molecular Templates, For: Apr 20

Thu, 24 Apr 2025 17:00:00 -0400

si-local-file:///var/storage/secattach/20250424/24684637.html

Calidi Biotherapeutics (CLDI) Announces CEO Change

Wed, 23 Apr 2025 08:00:43 -0400

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer (“CEO”), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi (“Board”), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board.

“We are pleased to welcome Eric as Calidi’s new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and

Calidi Biotherapeutics (CLDI) Announces CEO Change

Wed, 23 Apr 2025 08:00:43 -0400

Calidi Biotherapeutics (CLDI) Announces CEO Change

Wed, 23 Apr 2025 08:00:43 -0400

Calidi Biotherapeutics (CLDI) Announces CEO Change

Wed, 23 Apr 2025 08:00:43 -0400

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

Wed, 23 Apr 2025 08:00:00 -0400

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer (“CEO”), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi (“Board”), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board.

“We are pleased to welcome Eric as Calidi’s new CEO, given his deep experience in life science leadership with a focus on

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

Wed, 23 Apr 2025 08:00:00 -0400

“We are pleased to welcome Eric as Calidi’s new CEO, given his deep experience in life science leadership with a focus on

Form 8-K Molecular Templates, For: Feb 20

Wed, 26 Feb 2025 17:28:00 -0400

si-local-file:///var/storage/secattach/20250226/24411618.html

Form 8-K Molecular Templates, For: Feb 20

Wed, 26 Feb 2025 17:28:00 -0400

si-local-file:///var/storage/secattach/20250226/24411618.html

Form SCHEDULE 13G/A Molecular Templates, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Wed, 12 Feb 2025 15:53:00 -0400

si-local-file:///var/storage/secattach/20250212/24336269.html

Form SCHEDULE 13G/A Molecular Templates, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Wed, 12 Feb 2025 15:53:00 -0400

si-local-file:///var/storage/secattach/20250212/24336269.html

Molecular Templates (MTEM) Announces Resignations of Harold E. Selick, David R. Hoffmann, Kevin M. Lalande, Eric E. Poma, Gabriela Gruia, and Corsee Sanders from Board

Thu, 02 Jan 2025 16:18:36 -0400

On December 31, 2024, Harold E. Selick, David R. Hoffmann, Kevin M. Lalande, Eric E. Poma, Gabriela Gruia, and Corsee Sanders each resigned from the Board of Directors (the “Board”) of Molecular Templates (NASDAQ: MTEM) effective as of 11:59 pm EST on December 31, 2024. Additionally, Dr. Poma resigned from his roles as Chief Executive Officer, Chief Scientific Officer, Treasurer and Interim Chief Financial Officer of the Company effective as of 11:59 pm EST on December 31, 2024. The members of the Board did not resign from their positions over any disagreements with the Company’s Board or management.

Molecular Templates (MTEM) Announces Resignations of Harold E. Selick, David R. Hoffmann, Kevin M. Lalande, Eric E. Poma, Gabriela Gruia, and Corsee Sanders from Board

Thu, 02 Jan 2025 16:18:36 -0400

Form 8-K Molecular Templates, For: Dec 30

Thu, 02 Jan 2025 16:14:00 -0400

si-local-file:///var/storage/secattach/20250102/24161747.html

Form 8-K Molecular Templates, For: Dec 30

Thu, 02 Jan 2025 16:14:00 -0400

si-local-file:///var/storage/secattach/20250102/24161747.html

Molecular Templates (MTEM) Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

Thu, 19 Dec 2024 16:12:37 -0400

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of the Staff’s determination pursuant to Nasdaq Listing Rule 5101 that the Company is a “public shell,” and that, in the view of the Staff, the continued listing of the Company’s securities was no longer

Form 8-K Molecular Templates, For: Dec 16

Thu, 19 Dec 2024 16:11:00 -0400

si-local-file:///var/storage/secattach/20241219/24127109.html

Form 8-K Molecular Templates, For: Dec 16

Thu, 19 Dec 2024 16:11:00 -0400

si-local-file:///var/storage/secattach/20241219/24127109.html